{
    "nctId": "NCT00645541",
    "briefTitle": "Axillary Reverse Mapping for Invasive Carcinoma of the Breast",
    "officialTitle": "Axillary Reverse Mapping for Invasive Carcinoma of the Breast",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Identification Rate for Feasibility of ARM in Patients Undergoing Axillary Lymph Node Dissection for breast cancer therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with invasive carcinoma of the breast planning to undergo axillary lymph node dissection at M. D. Anderson Cancer Center.\n* Eastern Cooperative Oncology Group (ECOG) performance status of equal to or less than 3.\n\nExclusion Criteria:\n\n* Patients with known allergies to blue dye or other contraindications to Lymphazurin.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}